Elizabeth Dater Covance Inc CVD-N TOP PICK Jul 09, 2004

To a lot of testing and research for larger biotech companies. In a sweet spot.

Given with what's going on with Vioxx and Cellebrex, this company is very important as the FDA will be asking for lengthier testing on these areas. Looks on this as a fabulous growth story.

Largest company in the area of contract research for pharmaceuticals. They do drug trials and research for the large pharmaceutical and biotech companies. Had consistently traded at 25X-30X earnings but are now at 11X earnings. Great growth prospects ahead. Think they can grow at 15%-20% a year starting in 2010.

(A Top Pick Apr 8/09. Up 60.88%.) Still a buy.